Logo image
Back
Efficacy and Tolerability of Non-invasive Brain Stimulation in Pediatric Refractory Epilepsy: A Systematic Review and Meta-analysis (P1-10.005)
Abstract   Peer reviewed

Efficacy and Tolerability of Non-invasive Brain Stimulation in Pediatric Refractory Epilepsy: A Systematic Review and Meta-analysis (P1-10.005)

Asmaa Mhanna and Aaron Boes
Neurology, Vol.106(11_Supplement_1)
06/09/2026
DOI: 10.1212/WNL.0000000000215422

View Online

Abstract

Objective This study aimed to systematically review and meta-analyze the available literature on the efficacy and tolerability of non-invasive brain stimulation (NIBS) in pediatric refractory epilepsy. Background Pediatric refractory epilepsy presents significant treatment challenges, with approximately 30% of children remaining unresponsive to pharmacologic therapies. NIBS, including repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), has emerged as a potential adjunctive treatment. Design/Methods A systematic search of PubMed, Embase, and the Cochrane Library was conducted from inception till August 2025. We included RCTs and single-arm intervention studies assessing the effects of rTMS or tDCS in patients aged ≤18 years with refractory epilepsy. The primary outcome was the change in seizure frequency (SF) from baseline at 4–8 weeks post-intervention. Secondary outcomes included the change in interictal epileptiform discharges (IEDs), the proportion of patients achieving >50% seizure reduction, and the incidence of reported side effects. Results Eight studies were included with a total of 229 patients: four RCTs (n=125; 76 in intervention group, 49 in sham group) and four single-arm studies (n=104). A random-effects meta-analysis of the RCTs showed that rTMS/tDCS significantly reduced seizure frequency compared to sham (SMD: −0.422; 95% CI: −0.839 to −0.004; p = 0.048, I2 = 16%). IEDs were also significantly reduced at 4–8 weeks post intervention (MD: −14.31; 95% CI: −27.57 to −1.05; p = 0.034). In the pooled analysis of single-arm studies, 41.1% of patients (95% CI: 27.5% to 56.2%, I2 = 38%) achieved >50% seizure reduction. Adverse events were generally mild and transient, including transient skin erythema, itching, mild headache, and scalp discomfort. No serious complications were reported. Conclusions NIBS appears to be a safe and promising adjunctive treatment for children with refractory epilepsy, demonstrating significant short-term reductions in SF and IEDs. Larger, high-quality RCTs with standardized protocols are needed to validate these findings and inform clinical practice.

Details

Metrics

1 Record Views
Logo image